Payment overview · 2025
General Payments
$466.17
25 reported records · 9 companies
Healthcare provider profile · identity verified
Jawed H. Siddiqui, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLORISSANT, MO · NPI 1699705293
Verified facts
What the public records show
CMS Open Payments records show Jawed H. Siddiqui, M.D. received $466.17 in general payments during 2025 across 25 reported records.
Axsome Therapeutics, Inc. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Rexulti, Trintellix.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Auvelity by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $214.52 | 46.0% | 13 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.43 | 12.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.05 | 10.7% | 2 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $43.75 | 9.4% | 2 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $28.26 | 6.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.25 | 3.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.24 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.01 | 3.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.66 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $466.17 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $214.52 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $28.26 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
131 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1013 | 174 |
| Baclofen | Baclofen | 540 | 165 |
| Meloxicam | Meloxicam | 459 | 128 |
| Gabapentin | Gabapentin | 383 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 312 | 85 |
| Omeprazole | Omeprazole | 286 | 81 |
| Tizanidine Hcl | Tizanidine Hcl | 282 | 74 |
| Cephalexin | Cephalexin | 273 | 131 |
| Furosemide | Furosemide | 269 | 83 |
| Amoxicillin | Amoxicillin | 265 | 98 |
| Eliquis | Apixaban | 263 | 48 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 262 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 261 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 84 |
| Methocarbamol | Methocarbamol | 245 | 108 |
| Diclofenac Sodium | Diclofenac Sodium | 244 | 88 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 216 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 50 |
| Tramadol Hcl | Tramadol Hcl | 202 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 73 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 185 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 34 |
| Metformin Hcl | Metformin Hcl | 160 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 46 |
| Trazodone Hcl | Trazodone Hcl | 152 | 34 |
| Carvedilol | Carvedilol | 147 | 51 |
| Famotidine | Famotidine | 147 | 44 |
| Topiramate | Topiramate | 140 | 23 |
| Montelukast Sodium | Montelukast Sodium | 138 | 43 |
| Lisinopril | Lisinopril | 135 | 35 |
| Losartan Potassium | Losartan Potassium | 133 | 46 |
| Methylprednisolone | Methylprednisolone | 133 | 58 |
| Trintellix | Vortioxetine Hydrobromide | 131 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 46 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 49 |
| Levetiracetam | Levetiracetam | 123 | 34 |
| Divalproex Sodium | Divalproex Sodium | 122 | 25 |
| Ibuprofen | Ibuprofen | 115 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 32 |
| Azithromycin | Azithromycin | 109 | 53 |
| Jardiance | Empagliflozin | 102 | 19 |
| Simvastatin | Simvastatin | 102 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 42 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 93 | 43 |
| Mirtazapine | Mirtazapine | 93 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 32 |
| Pregabalin | Pregabalin | 84 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 23 |
| Fluconazole | Fluconazole | 78 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 58 |
| Sertraline Hcl | Sertraline Hcl | 76 | 21 |
| Buspirone Hcl | Buspirone Hcl | 74 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 16 |
| Potassium Chloride | Potassium Chloride | 74 | 23 |
| Glipizide | Glipizide | 73 | 12 |
| Clonidine Hcl | Clonidine Hcl | 72 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 14 |
| Linzess | Linaclotide | 70 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 27 |
| Ozempic | Semaglutide | 68 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 46 |
| Allopurinol | Allopurinol | 64 | suppressed |
| Dutasteride | Dutasteride | 63 | 13 |
| Farxiga | Dapagliflozin Propanediol | 63 | 23 |
| Telmisartan | Telmisartan | 63 | 14 |
| Rybelsus | Semaglutide | 60 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 35 |
| Nystatin | Nystatin | 50 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 44 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 19 |
| Lorazepam | Lorazepam | 43 | 12 |
| Prednisone | Prednisone | 43 | 15 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 12 |
| Santyl | Collagenase Clostridium Hist. | 38 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 35 | 17 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 30 | suppressed |
| Permethrin | Permethrin | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Ramipril | Ramipril | 28 | 11 |
| Spironolactone | Spironolactone | 28 | 11 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | 12 |
| Naproxen | Naproxen | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 12 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 18 | suppressed |
| Fluorometholone | Fluorometholone | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $466.17 · 25 records | Axsome Therapeutics, Inc. | AUSTEDO XR, Auvelity, Belbuca, LEQVIO, MOUNJARO, REXULTI, ROXYBOND, TRINTELLIX, WatchPATONE, XTAMPZA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Axsome Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error